The recent trading activity involving Itron, Inc. (NASDAQ:ITRI), highlights insider movement within the company. On May 26, 2026, Christopher E. Ware, who serves as Senior Vice President, General Counsel, and Corporate Secretary at Itron, disposed of a total value of $16,451 in the firm's common stock.
Details of the disposal show that Mr. Ware sold 195 shares, executing the sale at a price point of $84.3667 per share. The text specifies that these particular shares were automatically liquidated to satisfy tax withholding obligations connected to the vesting of a restricted stock unit award. Following this specific transaction, records indicate that Mr. Ware's direct holdings of Itron common stock amounted to 30,311 shares.
Beyond the executive trading report, recent corporate financial data provides additional context for investors evaluating ITRI’s valuation and operational standing. For instance, in its first-quarter earnings report for 2026, Itron Inc. announced results that surpassed consensus expectations set by analysts. The company reported an earnings per share of $1.49, which was higher than the projected figure of $1.23. Furthermore, revenue also demonstrated strength, reaching $587 million when the anticipated figure was $572.09 million.
Despite these positive financial disclosures regarding performance and outperformance relative to forecasts, a key analyst firm issued an adjustment that introduced caution. Roth/MKM revised its price target for Itron, lowering it from $150 to $136, while simultaneously maintaining a 'Buy' rating on the stock. The firm explicitly attributed this downward revision to what it characterized as a more subdued near-term revenue growth outlook. This reduced forecast is linked specifically to factors such as complex projects and temporary regulatory dynamics.
Current market metrics for Itron provide additional context. The stock currently trades at $85.30, carrying a reported market capitalization of $3.78 billion and maintaining a P/E ratio of 13.6. Independent analysis from InvestingPro suggests that, relative to its Fair Value, Itron may be slightly undervalued. This valuation perspective is reinforced by analysts who have set price targets ranging between $112 and $145.
In summary, the recent developments at Itron reflect a dichotomy of internal confidence and external market caution. While the company demonstrated strong execution in Q1 2026 earnings, surpassing both revenue and EPS estimates, the combination of an executive stock sale coupled with a lowered price target by an analyst firm suggests that investors should weigh robust quarterly performance against potential near-term sector headwinds.